Thefirstphospholipaseinhibitorfromthe serum
of Viperaammodytes ammodytes
Jernej S
ˇ
ribar
1
, Lidija Kovac
ˇ
ic
ˇ
1
, Petra Dras
ˇ
kovic
ˇ
1
, Grazyna Faure
2
and Igor Kriz
ˇ
aj
1
1 Department of Molecular and Biomedical Sciences, Joz
ˇ
ef Stefan Institute, Ljubljana, Slovenia
2 Unite
´
d’Immunologie Structurale, Institut Pasteur, Paris, France
In many snake venoms the major proportion of the
toxic components are secretory phospholipases A
2
(sPLA
2
). Snakes have long been known to be resistant
to their own venom. One ofthe reasons for this is the
presence ofthe so-called neutralizing factors in the
blood of these animals. Several proteins have been iso-
lated from snake sera that exhibit antihemorrhagic,
antineurotoxic or antimyotoxic properties. Many have
been characterized as sPLA
2
inhibitors (PLIs) and are
found in both venomous and nonvenomous snake spe-
cies [1–3].
Based on their structural characteristics, PLIs have
been classified into three groups: a, b and c [4]. PLI-a
are 75–120 kDa globular glycoproteins, consisting of
three to six noncovalently bound 20–25 kDa subunits
[4–7]. They all possess a sequence similar to the carbo-
hydrate-recognition domain of Ca
2+
-dependent lectins.
The binding site for sPLA
2
on this type of PLI has,
however, been suggested to be distinct fromthe carbo-
hydrate-binding site ofthe homologous Ca
2+
-depen-
dent lectin [8]. This type of PLI has, to date, been
found in species of snakes belonging to the Viperidae
family where it specifically inhibits the acidic type IIA
sPLA
2
molecules fromthe species’ own venom [1,2].
The first PLI-b was isolated fromthe blood of
Agkistrodon blomhoffii siniticus [4]. It is a 160 kDa
Keywords
ammodytoxin; inhibitor; secretory
phospholipase A
2
; snake serum; Vipera
ammodytes ammodytes
Correspondence
I. Kriz
ˇ
aj, Department of Molecular and
Biomedical Sciences, Joz
ˇ
ef Stefan Institute,
Jamova 39, SI-1000 Ljubljana, Slovenia
Fax: +386 1477 3984
Tel: +386 1477 3626
E-mail: igor.krizaj@ijs.si
(Received 26 June 2007, revised 2 October
2007, accepted 4 October 2007)
doi:10.1111/j.1742-4658.2007.06127.x
Ammodytoxins are neurotoxic secretory phospholipase A
2
molecules, some
of the most toxic components ofthe long-nosed viper (Vipera ammo-
dytes ammodytes) venom. Envenomation by this and by closely related
vipers is quite frequent in southern parts of Europe and serotherapy is used
in the most severe cases. Because of occasional complications, alternative
medical treatment of envenomation is needed. In the present study, ammo-
dytoxin inhibitor was purified fromtheserumof V. a. ammodytes using
two affinity procedures and a gel exclusion chromatography step. The
ammodytoxin inhibitorfrom V. a. ammodytesserum consists of 23- and
25-kDa glycoproteins that form an oligomer, probably a tetramer, of about
100 kDa. N-terminal sequencing and immunological analysis revealed that
both types of subunit are very similar to c-type secretory phospholipase A
2
inhibitors. The ammodytoxin inhibitorfrom V. a. ammodytesserum is a
potent inhibitorofphospholipase activity and hence probably also the
neurotoxicity of ammodytoxins. Discovery ofthe novel natural inhibitor of
these potent secretory phospholipase A
2
toxins opens up prospects for the
development of new types of small peptide inhibitors for use in regulating
the physiological and pathological activities of secretory phospho-
lipases A
2
.
Abbreviations
AIVAS, ammodytoxin inhibitorfromViperaammodytes serum; Atx, ammodytoxin; AtxC, ammodytoxin C; CB, basic subunit of crotoxin;
CICS, crotoxin inhibitorfrom Crotalus serum; CIM, convective interactive media; CNF, Crotalus neutralizing factor; ConA, concanavalin A;
LL, lentil lectin; PLA
2
, phospholipase A
2
; PLI, PLA
2
inhibitor; PVDF, poly(vinylidene difluoride); RU, response unit; SPR, surface plasmon
resonance; VAAS, Vipera a. ammodytes serum; sPLA
2
, secretory phospholipase A
2
; WGA, wheat germ agglutinin.
FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS 6055
globular glycoprotein, comprising three identical sub-
units of 50 kDa. The subunits contain nine leucine-
rich repeats that are probably involved in sPLA
2
binding [9]. PLI-b is not present exclusively in snakes
of the Viperidae family. This type of PLI has also been
isolated from a nonvenomous snake Elaphe quadrivirg-
ata. Unlike the PLI-b from A. b. siniticus, the trimer
from E. quadrivirgata comprises two homologous types
of 50 kDa subunits [10]. These two types of PLI were
found to inhibit only some type II sPLA
2
molecules.
The majority of characterized PLIs isolated from
snake serum belong to the c-type group. They are 90–
130 kDa acidic glycoproteins, composed of three to six
noncovalently bound 20–31 kDa subunits [2]. They are
characterized by a three-finger motif consisting of a
unique pattern of cysteine residues that is found in
various proteins with different biological functions,
from a serine protease inhibitor to an ion channel
blocker. PLI-c molecues are present in the sera of
snakes fromthe families Viperidae, Colubridae, Elapi-
dae, Boiidae and Hydrophidae, where they appear to be
less specific than a- and b-type PLIs because they are
able to inhibit sPLA
2
from groups I, II and III [11].
Besides snake venom sPLA
2
molecules, which exert
neurotoxic, myotoxic, cardiotoxic and other pharmaco-
logical effects [12], a number of other types of phos-
pholipase A
2
(PLA
2
) have been discovered in
mammals [13]. In addition to digesting phospholipids,
these molecules are involved in many other physiologi-
cal processes [14,15]. In some processes, such as
exocytosis ⁄ endocytosis, inflammation, blood coagula-
tion, ischaemia and antibacterial defence, the sPLA
2
molecule participates as an enzyme, whereas in other
processes, like cell migration, cell proliferation and
inhibition of blood coagulation, the sPLA
2
molecule
acts as a ligand for different cellular receptors [16–18].
Obviously, strict regulation ofthe enzymatic and
receptor-binding activities of sPLA
2
is crucial to avoid
pathological conditions such as cancer, atherosclerosis
and acute respiratory distress syndrome, as well as to
neutralize the toxic activity of venom sPLA
2
. There is
a great need for a wide range of new inhibitors of
sPLA
2
that are highly specific. Given the similarity
between some tissue receptors for sPLA
2
and PLI (e.g.
between the M-type sPLA
2
receptor and PLI-a) the
characterization of new snake PLIs may eventually
lead to the discovery of novel tissue receptors for
sPLA
2
, resulting in a better understanding ofthe patho-
physiology of this group of enzymes.
In this work we present the characterization of the
first PLI fromtheserumofthe most dangerous Euro-
pean snake, Viperaammodytes ammodytes. This PLI
potently inhibits the enzymatic and therefore very
probably also the neurotoxic activity of ammodytoxins
(Atx), presynaptically toxic sPLA
2
and the main toxic
components of this venom.
Results and Discussion
Detection of Atx inhibitorfrom V. a. ammodytes
serum by surface plasmon resonance
Crotoxin inhibitorfrom Crotalus serum (CICS) binds
also to Atx [19], so we worked on the assumption that
a structurally similar PLI that we named ammodytoxin
inhibitor fromViperaammodytesserum (AIVAS)
exists in theserumof V. a. ammodytes (VAAS). This
assumption was verified by immobilizing anti-CICS
IgG on a CM-5 surface plasmon resonance (SPR) sen-
sor chip. An aliquot of VAAS was injected over this
chip, allowing the proteins to bind, followed by ammo-
dytoxin C (AtxC). AtxC interaction with the antibody-
retained proteins is shown in Fig. 1A. The result
clearly demonstrated the presence of CICS-like
rb
VAAS
AtxC
rb
VAAS
CBa
A
B
retention time (s)
retention time (s)
response (RU)
ANTI-CICS
ANTI-CICS
response (RU)
200
100
90
80
70
60
50
40
30
20
10
–10
0
180
160
140
120
100
80
60
40
20
0
–50 0 50 100 150 200
–50 0 50 100 150
–20
Fig. 1. Detection of CICS-like molecules in VAAS. Rabbit anti-CICS
IgG was covalently immobilized on an SPR CM-5 sensor chip.
Serum was injected over the sensor chip, followed by sPLA
2
AtxC
(A) or CB (B). Finally, running buffer (rb) was injected and the disso-
ciation rate observed. Data were analyzed using the
BIAEVALUATION
3.1 software (Biacore). RU, response unit.
Ammodytoxin inhibitorfromViperaammodytesserum J. S
ˇ
ribar et al.
6056 FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS
molecules in VAAS, which bind AtxC. The bound
AtxC was not dissociated by running buffer, indicating
a strong interaction between AtxC and its binding
protein(s) in the serum. In a control experiment, the
crotoxin basic subunit (CB) was injected instead of
AtxC (Fig. 1B). It was bound to CICS-like molecule(s)
in VAAS, but the interaction was weaker than that of
AtxC, as judged by its dissociation by running buffer.
When CICS was attached via anti-CICS IgG on the
SPR chip, however, the situation was reversed [19]. In
this case, CB bound to CICS with much higher affinity
than Atx, revealing the specificity ofthe sPLA
2
-bind-
ing proteins for the homologous sPLA
2
toxins from
their species’ own venom, consistent with the self-pro-
tective function ofserum sPLA
2
-binding molecules [3].
Affinity labelling of AIVAS
Affinity labelling was used to obtain structural infor-
mation on AIVAS. Chemical cross-linking of
125
I-labelled AtxC to VAAS resulted in three specific
adducts of 114, 74 and 40 kDa apparent molecular
mass (Fig. 2, lanes 1 and 2). The molecular mass of
AtxC is 14 kDa, and, assuming the association of one
molecule of AtxC with one molecule of AtxC-binding
protein, the apparent molecular masses of Atx-binding
proteins in theserum are 100, 60 and 26 kDa. Based
on the probable structural relatedness between AIVAS
and CICS (Fig. 1A), the species with apparent molecu-
lar masses of 60 and 100 kDa probably correspond to
a dimer and a tetramer ofthe basic subunit of about
26 kDa.
For most PLIs, however, a 1 : 1 stoichiometry of
binding of sPLA
2
to the PLI subunit has been
reported. For example, PLI-a from Bothrops asper
inhibited the venom myotoxic sPLA
2
on a 1 : 1 basis
[20]. The same was shown for the PLI-b trimer from
A. b. siniticus, which bound three molecules of sPLA
2
[9]. In the case of a c-type PLI, 1 : 1 stoichiometry of
binding between CB, a basic sPLA
2
subunit of crotox-
in, and the Crotalus neutralizing factor (CNF) subunit
has been suggested [21], although other results indicate
that only one molecule of CB is bound per CICS
oligomer [22].
sPLA
2
-binding characteristics of AIVAS
To check the sPLA
2
-binding profile of AIVAS, aliqu-
ots ofserum were affinity labelled in the presence of
different types of sPLA
2
at 2 lm concentration
(Fig. 2). Atx and ammodytin L, a myotoxic sPLA
2
homologue from V. a. ammodytes venom, were the
most potent inhibitors of formation ofthe specific
adducts between
125
I-labelled AtxC and AIVAS. Inter-
estingly, a nontoxic sPLA
2
, ammodytin I
2
from
V. a. ammodytes venom, also blocked specific labelling
very effectively, a feature not observed in the case of
CICS, which does not inhibit phospholipase activity or
bind nontoxic sPLA
2
[19]. Practically no inhibition
was, however, observed with type II sPLA
2
molecules
structurally related to Atx (i.e. agkistrodotoxin, crotox-
in and human sPLA
2
-IIA), or with type I sPLA
2
mole-
cules, such as notexin, Oxyuranus s. scutellatus sPLA
2
,
b-bungarotoxin and taipoxin, and type III bee venom
PLA
2
. AIVAS obviously very specifically binds
V. a. ammodytes venom sPLA
2
, Atx and ammody-
toxins, probably to protect the snake fromthe action
of its own venom sPLA
2
[3].
The pH stability of AIVAS was determined by incu-
bating aliquots of VAAS at different pH values for
30 min at room temperature. Following incubation,
the pH was adjusted to 8.2 and affinity labelling with
125
I-labelled AtxC was performed (Fig. 3). While the
intensity ofthe specific adduct at 40 kDa was slightly
reduced only after exposure of VAAS to a pH of
< 6.0, the intensities ofthe bands at 74 and 114 kDa
were more pH dependent. Given the structural similar-
ity between AIVAS and CICS, adducts at 74 and
114 kDa probably represent
125
I-AtxC-labelled associa-
tions of two and four inhibitor subunits. We assume
123
86
44.6
31.4
M [kDa]
T
AxtC
AxAt
AnI
2
t
AnL
t
Atxg
huI -PLAIA
2
x
notei
n
OS
2
crotoxin
-B x
ut
ta oxinip
bvPLA
2
Fig. 2. Detection of Atx-binding proteins in VAAS and analysis of
their sPLA
2
-binding profile. Serum aliquots were affinity labelled
with
125
I-labelled AtxC in the absence or presence of indicated
sPLA
2
molecules at a concentration of 2 lM. The samples were
analyzed by SDS ⁄ PAGE (10% acrylamide gel) under reducing condi-
tions and the gel autoradiographed. The positions of specific
adducts are indicated by arrows. Agtx, agkistrodotoxin; Atn, ammo-
dytins;Atx, ammodytoxins; b-Butx, b-bungarotoxin; bvPLA
2
, bee
venom PLA
2
; huIIA-PLA
2
, human type IIA sPLA
2
;OS
2
, Oxyuranus
scutellatus sPLA
2
-2.
J. S
ˇ
ribar et al. Ammodytoxin inhibitorfromViperaammodytes serum
FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS 6057
that the oligomerization of subunits is reduced by
exposure to low pH, but not to the same extent as
their AtxC-binding ability.
As demonstrated in Fig. 3, the binding of
125
I-
labelled AtxC to AIVAS is independent ofthe pres-
ence of divalent cations.
AIVAS is a glycoprotein
PLI molecules isolated from snake sera are typically
glycoproteins [2,11,23,24]. However, glycosylation of
PLI does not appear to play a role in binding sPLA
2
[11]. To check whether AIVAS contains carbohydrate,
aliquots of VAAS were incubated with different gel-
immobilized lectins, lentil lectin (LL), wheat germ
agglutinin (WGA) and concanavalin A (ConA), and
analysed for AIVAS in the bound and breakthrough
fractions. AIVAS bound to all three lectins tested and
is thus a glycoprotein (data not shown). Binding was
strongest to LL, which was therefore chosen for the
first step in the isolation procedure.
Purification of AIVAS
In the initial step, VAAS was chromatographed on an
LL-affinity column. The bound material was further
fractionated by AtxC affinity chromatography. The
attempt to purify biologically active AIVAS on an
AtxC–Sepharose column [25] was unsuccessful owing
to the strong binding of AIVAS on the column and
because ofthe denaturing conditions (pH 2.8) needed
for elution. Inactivation of other PLIs on low-pH elu-
tion has also been reported by other authors [20,24].
Another chromatographic medium was chosen that
would allow rapid analysis with the same ligand. AtxC
was immobilized on convective interactive media
(CIM) monolithic disks and, by rapid elution at
pH 2.8 followed by immediate elevation ofthe pH of
the samples to 7.4, inactivation of AIVAS was
avoided. SDS ⁄ PAGE analysis showed protein bands
with apparent molecular masses of 23–25 kDa and
90 kDa (Fig. 4).
In an attempt to separate the 23 and 25 kDa pro-
teins from a 90 kDa protein, fraction 8 from CIM–
AtxC affinity chromatography (Fig. 4) was subjected
to analytical gel-filtration on an FPLC Superdex HR
10 ⁄ 30 column. The material was eluted in two strongly
overlapping peaks. The major peak corresponded to a
molecular mass slightly below 200 kDa, and the minor
peak corresponded to a mass slightly above 100 kDa
(Fig. 5A). Fractions were analysed by SDS ⁄ PAGE
under reducing conditions and the gels were silver
stained (Fig. 5B). In fraction 7, besides a major protein
band at 90 kDa, two proteins with apparent molecular
masses of 23 and 25 kDa were detected. In fraction 8,
however, only the two low-molecular-mass proteins
were found, under both reducing and nonreducing
conditions. These analyses, in addition, revealed that
under nondenaturing conditions on the gel-filtration
column, the low-molecular-mass proteins oligomerize,
which is a common feature of PLIs [11].
31.4
44.6
86
123
M [kDa]
5.0
pH:
5.5
6.
0
6.5
7.
0
7.
5
8.0
8.
5
9.0
EG
AT
EDTA
Fig. 3. Effect of pH and divalent ions on the binding of AtxC to
AIVAS. Aliquots ofserum were exposed to different pH levels
(5.0–9.0) at room temperature and then affinity labelled at pH 8.2
with
125
I-labelled AtxC. Two samples were affinity labelled in the
presence of EGTA or EDTA to probe the dependency of binding on
the presence of divalent cations. All samples were analyzed by
SDS ⁄ PAGE (10% acrylamide gel) under reducing conditions and
the gel was autoradiographed. The positions of specific adducts are
indicated by arrows.
72
50
24
17
LLE
fr
.5
.6fr
.7fr
fr. 8
fr. 9
.fr
10
100
130
M [kDa]
Fig. 4. Separation of AIVAS on AtxC affinity chromatography. The
eluate from LL–Sepharose chromatography was chromatographed
on a CIM–AtxC affinity disk. The fractions were analyzed by
SDS ⁄ PAGE (12.5% acrylamide gel) under reducing conditions and
the gel was silver stained. In lane LLE, the composition ofthe frac-
tion retained by LL and applied on the AtxC affinity chromatography
is shown, and lanes fr.5 to fr.10 display the composition of frac-
tions eluted fromthe toxin affinity chromatography. The positions
of AIVAS are indicated by arrowheads.
Ammodytoxin inhibitorfromViperaammodytesserum J. S
ˇ
ribar et al.
6058 FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS
The purified AIVAS retained the ability to bind
AtxC, as demonstrated in an affinity labelling experi-
ment of
125
I-labelled AtxC and the gel-filtration frac-
tions 7 and 8 (Fig. 6). Fraction 8, which contained
only the proteins of 23 and 25 kDa, gave three specific
adducts of apparent mass 40, 74 and 114 kDa. AIVAS
is therefore a tetramer that is noncovalently associated
with subunits of 23 and 25 kDa. The ratio between the
23 and 25 kDa subunits in the complex is currently
unknown. The results suggest that only one molecule
of Atx is bound by the tetramer, as proposed also for
the structurally similar CICS [22].
AIVAS is structurally related to c-type PLIs
The proteins from fractions 7 and 8 were electroblot-
ted to a poly(vinylidene difluoride) (PVDF) membrane
and their N-terminal sequences were determined. The
25-kDa bands from each fraction contained two
sequences – a major sequence (VAA_1) and a similar
minor sequence (VAA_2). The ratio between the
major and the minor sequences was 80 : 20. In the
23-kDa bands, only the VAA_1 sequence was present
(Fig. 7A). Comparison ofthe sequences with protein
sequence databases (Fig. 7B) showed that VAA_1 is
very similar to the 25 kDa subunit ofthe c-type PLI
from theserumof A. b. siniticus [4], to the CNF from
Crotalus durissus terrificus and 23 ⁄ 25 kDa CICS from
the same snake serum [21,22]. On the other hand, the
VAA_2 sequence shows strong similarity to the
20 kDa subunit ofthe c-type PLI fromtheserum of
A. b. siniticus [4] and the minor 23 kDa sequence of
CICS [22]. The immunoblot in Fig. 5C confirms that
the isolated AIVAS of 23 and 25 kDa indeed belong
structurally to the c-type PLIs. Thus, both proteins
were cross-reactive with anti-CICS IgG which,
however, did not recognize the 90 kDa Atx-binding
protein. The N-terminal amino acid sequence of the
latter shows similarity to immunoglobulin heavy
chain (E-V-Q-L-V-E-X-G-Q-D). This suggests that
the snake can produce auto-antibodies against toxic
components in its own venom as part of its self-pro-
tection system, a feature observed here for the first
time.
A
B
absorbance (mAU)
M (kDa)
Fig. 5. Final purification of AIVAS and its
partial characterization. (A) Fraction 8 from
the AtxC-affinity purification step was chro-
matographed on a Superdex HR 10 ⁄ 30
column. Numbers 1–18 indicate fractions
eluted fromthe column. (B) Proteins in
fractions 7, 8 and 9 were analyzed by
SDS ⁄ PAGE (12.5% acrylamide gel) under
reducing conditions and the gel was silver
stained. Protein bands of apparent molecular
weights 23, 25 and 90 kDa are indicated by
arrows. (C) Fractions 7 and 8 were analyzed
by SDS ⁄ PAGE under reducing conditions,
transferred to a nitrocellulose membrane
and immunostained using polyclonal anti-
CICS IgG and the enhanced chemilumines-
cence (ECL) detection system. Proteins of
23 and 25 kDa (arrows) are AIVAS structur-
ally related to PLI-c. (D) AIVAS was degly-
cosylated using protein N-glycosidase F and
analysed by SDS ⁄ PAGE as described above.
A decrease ofthe molecular mass revealed
that both AIVAS subunits contain 3–4 kDa
of N-linked carbohydrates.
J. S
ˇ
ribar et al. Ammodytoxin inhibitorfromViperaammodytes serum
FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS 6059
The deglycosylation of AIVAS using protein N-gly-
cosidase F resulted in a reduction ofthe molecular
mass of both subunits by 3–4 kDa (Fig. 5D). Based on
this, it can be concluded that both subunits are gly-
cosylated and that the difference in molecular mass
between them stems fromthe difference in composition
of their polypeptide chains. The N-terminal sequence
of the subunits is identical, so the 23 kDa subunit is
probably the C-terminally truncated form of the
25 kDa subunit, the explanation which pertains also in
the case of CICS subunits [22]. The extent of glycosyl-
ation of AIVAS is similar to that found in homolo-
gous c-type PLIs. For example, the molecular mass of
the CNF subunit calculated from its amino acid
sequence differs, by about 3 kDa, from that deter-
mined experimentally, because of glycosylation [23].
Similarly, treatment of CgMIP-I from Cerrophidion
(Bothrops) godmani serum with protein N-glycosi-
dase F reduced the molecular mass of its subunit by
approximately 3 kDa [24].
Inhibition ofphospholipase activity by AIVAS
Isolated AIVAS (fraction 8 in Fig. 5B) was incubated
at room temperature with AtxC and then assayed for
phospholipase activity. AIVAS, in a 2 : 1 molar ratio
to AtxC, lowered thephospholipase activity of AtxC
by more than 80%. At the same molar ratio, CICS
reduced the activity of AtxC by only 45% [19], provid-
ing further evidence for the preference ofserum PLIs
for their own venom sPLA
2
molecules and in agree-
ment with an auto-envenomation protection role for
PLIs. Interestingly, the inhibition of crotoxin subunit
CB by CICS was very similar to that of AIVAS on
AtxC. At 1 : 1 and 2 : 1 molar ratios of CICS to CB,
the enzymatic activity of CB was reduced to 37 and
16%, respectively, ofthe starting activity [19], whereas
in the case of AIVAS and AtxC, at the same ratios, the
phospholipase activity of AtxC was reduced to 38 and
19%, respectively (Fig. 8). This indicates that structur-
ally, and thus also in terms ofthe sPLA
2
inhibition
mechanism, CICS and AIVAS are closely related.
AIVAS was probed also for its ability to inhibit the
phospholipase activity ofthe main structural types of
sPLA
2
. As presented in Fig. 8B, besides AtxC, AIVAS
inhibited efficiently only ammodytin I
2
, a nontoxic
sPLA
2
from V. a. ammodytes venom, as AtxC also a
monomeric type II sPLA
2
. A dimeric type II sPLA
2
(crotoxin), type I sPLA
2
molecules (b-bungarotoxin
and taipoxin) and a type III bee venom PLA
2
were
not significantly inhibited. The sPLA
2
-inhibition spec-
tra of AIVAS is in good agreement with the affinity
labelling competition results (Fig. 2) where also only
123
86
44.6
31.4
M [kDa]
LLE(T
)
LL )E(C
fr.7
fr.8
Fig. 6.
125
I-Labelled AtxC affinity labelling of purified AIVAS. Aliqu-
ots of LL-bound material (LLE), and fractions 7 and 8 from gel chro-
matography, were affinity labelled with
125
I-labelled AtxC. The
control experiment LLE (C) contained a 100-fold molar excess of
native AtxC over the radioactively labelled AtxC. The samples were
analyzed by SDS ⁄ PAGE (12.5% acrylamide gel) under reducing con-
ditions and the gel was autoradiographed. Three specific adducts
were formed, corresponding to molecular masses of 114, 74 and
40 kDa (arrows), as in the case of VAAS labelling in Fig. 2.
A
B
Fig. 7. Sequence analysis of AIVAS. AIVAS was electrotransferred
to a PVDF membrane and N-terminally sequenced. (A) The 23 kDa
band gave exclusively VAA_1 sequence, which was also the main
sequence in the 25 kDa band. In addition, the 25 kDa band con-
tained a sequence of low intensity (VAA_2), homologous to VAA_1.
(B) Protein sequence database search, using the
FASTA algorithm,
revealed the highest similarity of VAA_1 and VAA_2 with snake
serum c-type PLIs. PLI_20 and PLI_25 are the 20- and 25-kDa
subunits ofthe c-type PLI from Agkistrodon blomhoffii siniticus [4],
whereas CNF, CICS_23 ⁄ 25 and CICS_23minor are c-type PLIs from
Crotalus durissus terrificus [21,22]. A dot represents a position
where no amino acid residue could be assigned.
Ammodytoxin inhibitorfromViperaammodytesserum J. S
ˇ
ribar et al.
6060 FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS
some ofthe type II sPLA
2
s (AtxA and ammodytin I
2
)
efficiently inhibited the
125
I-AtxC labelling of AIVAS.
Preferential inhibition of type II sPLA
2
molecules
qualifies AIVAS as a subclass II c-PLI [11].
The neuroprotective effect of CICS has been sug-
gested to be the result of its action as a false soluble
receptor for presynaptically acting neurotoxins, pre-
venting them from binding to their receptors on pre-
synaptic membranes [22]. Besides specific binding to
neuronal receptors, the neurotoxic action of sPLA
2
molecules also depends on their phospholipase activity
[17]. Inhibition ofthephospholipase activity of an
sPLA
2
neurotoxin leads to its neutralization as a toxin,
and therefore AIVAS is expected to act as a natural
inhibitor of sPLA
2
neurotoxicity, similarly to CICS.
In summary, we have purified biologically active
sPLA
2
inhibitor AIVAS fromtheserumof V. a. am-
modytes. AIVAS is structurally related to c-type sPLA
2
inhibitors. It is a noncovalent tetramer of 23 and
25 kDa glycosylated subunits. AIVAS is a potent
inhibitor of Atx phospholipase activity, also suggesting
its action as a natural inhibitorof their neurotoxic
action. Studies ofthe structural basis ofthe interaction
between AIVAS and Atx will aid in designing novel
peptide inhibitors ofthephospholipase and hence neu-
rotoxic action of sPLA
2
molecules.
Experimental procedures
V. a. ammodytes serum
VAAS was obtained fromthe Institute of Immunology
Inc., Zagreb, Croatia. Blood from V. a. ammodytes was col-
lected by heart puncture, incubated for 30 min at 30 °C,
centrifuged at 3260 g for 20 min at 4 °C and theserum dec-
anted and stored at )20 °C.
Surface plasmon resonance
SPR experiments were performed at 25 °C, using a Biacore
Ò
2000 system (Biacore AB, Uppsala, Sweden). The running
and dilution buffer in all experiments was 10 mm Hepes,
pH 7.4, 150 mm NaCl, 5 mm CaCl
2
and 0.005% (w ⁄ v) P20
(Pharmacia, Uppsala, Sweden). After purification on CICS-
affinity chromatography, polyclonal rabbit anti-CICS IgG
was covalently immobilized on a CM-5 sensor chip, as pre-
viously described [19]. The SPR signal for immobilized rab-
bit anti-CICS IgG was found to be 2275 RU and 3422 RU,
corresponding to a protein surface concentration of
2275 pgÆmm
)2
and 3422 pgÆmm
)2
. To detect the presence of
CICS-like molecules in VAAS, 15 lL of diluted serum (pro-
tein concentration 0.25 mgÆmL
)1
) was injected for 1 min at
a flow rate of 20 lLÆmin
)1
. Immediately following that,
sPLA
2
, AtxC or CB
a
(one ofthe isoforms of CB), at 1–
6 lgÆmL, was injected for another 1 min followed by injec-
tion ofthe running buffer to observe the dissociation rate.
At the end of each run, the binding capacity ofthe sensor
chip was regenerated for 30 s with 20 mm HCl. Data were
analyzed using the biaevaluation 3.1 software (Biacore
AB) after subtracting control signals obtained from the
injection of sPLA
2
molecules on the control flow cell.
Affinity labelling
To 40 lL ofserum (0.15 mgÆmL
)1
of total protein), 10 lL
of 50 mm Hepes, pH 8.2, containing 150 mm NaCl and
0
20
40
60
80
100
120
0 0,5 1 1,5 2 2,5
molar ratio (SABP:AtxC)
relative enzymatic activity
A
B
Fig. 8. Determination ofthe capacity of AIVAS to inhibit phospholi-
pase activity. (A) Isolated AIVAS was incubated at room tempera-
ture for 30 min with a fixed concentration of AtxC at different
molar ratios and the remaining phospholipase activity was deter-
mined. The two-fold molar excess of AIVAS over AtxC lowered the
enzymatic activity of AtxC by approximately 81%. (B) AIVAS was
incubated with representatives of different structural types of
sPLA
2
at designated molar ratios and then the remaining phospholi-
pase activity was measured. The results shown represent the per-
centage ofthe full activity of an sPLA
2
(in the absence of AIVAS)
which remained following incubation ofthe enzyme with AIVAS.
Values are expressed as the mean ± SD of duplicates. AtnI
2
, am-
modytin I
2
; AtxC, ammodytoxin C; b-Butx, b-bungarotoxin; bvPLA
2
,
bee venom PLA
2
.
J. S
ˇ
ribar et al. Ammodytoxin inhibitorfromViperaammodytes serum
FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS 6061
2mm CaCl
2
(buffer A) with the addition of 0.625% (w ⁄ v)
Triton X-100 and 12.5 lLof
125
I-labelled AtxC to give a
final concentration of 10 nm were added and incubated for
30 min at room temperature in the presence or absence of
an unlabelled competitor (2 lm final concentration). Where
indicated, the Ca
2+
in buffer A was replaced with either
1mm EGTA or 1 mm EDTA. Disuccinimidyl suberate
(Pierce, Rockford, IL, USA) was added (100 lm final con-
centration), and, after 5 min, the cross-linking reaction was
stopped by the addition of SDS ⁄ PAGE sample buffer.
Samples were analyzed by SDS ⁄ PAGE and the gels were
dried and autoradiographed at )70 °C using Kodak
X-Omat AR films (Kodak, Rochester, NY, USA) [26].
To test the effect of pH on AIVAS, aliquots of VAAS
were diluted 30-fold in buffers with pH ranging from 5 to
9 and incubated for 30 min at room temperature, followed
by a 10-fold dilution in buffer A to adjust the pH back to
8.2. Affinity labelling was then performed as described
above.
Lectin-affinity chromatography
One-hundred-microlitre samples of LL–, WGA– and ConA–
Sepharose (Pharmacia) were separately equilibrated in buf-
fer A. Five-hundred microlitres of VAAS (1.5 mgÆmL
)1
)
was added to each gel suspension and incubated for 4 h at
4 °C with moderate agitation. Following a short centrifuga-
tion at 13 100 g for 30 s at 4 °C, the supernatant was
removed and the gels were washed with 5 mL of buffer A.
To elute bound proteins, the gels were agitated moderately
for 1 h at 4 °C in 500 lL ofthe following elution buffers:
0.5 m N-acetylglucosamine in buffer A for WGA–Sepharose
and 0.5 m Me-a-d-mannopyranoside in buffer A for ConA–
Sepharose and LL–Sepharose. Following a short centrifuga-
tion at 13 100 g for 30 s at 4 °C, the supernatants were
removed and the aliquots were analyzed by 10% (w ⁄ v) or
12.5% (w ⁄ v) SDS ⁄ PAGE [27] under reducing conditions
[0.5% (w ⁄ v) SDS, 50 mm dithiothreitol, 10% (v ⁄ v) glycerol,
30 mm Tris ⁄ HCl, pH 6.8], followed by silver staining [28].
As the initial step ofthe isolation of AIVAS from VAAS,
6 mL of VAAS (3.6 mgÆmL
)1
total protein) was incubated
with 3 mL of LL–Sepharose and the bound proteins were
eluted with 6 mL ofthe elution buffer under the conditions
described above.
CIM–AtxC affinity chromatography
A CIM Epoxy Disc (BIA Separations, Ljubljana, Slovenia)
was washed on an A
¨
KTA FPLC apparatus (Amersham
Pharmacia Biotech, Uppsala, Sweden) with buffer B (0.5 m
Na
2
HPO
4
, pH 8.2) at 1 mLÆmin
)1
until the absorbance
at 280 nm (A
280
) was zero. Two millilitres of AtxC
(2 mgÆmL
)1
in buffer B) was loaded at room temperature
on the disk at a flow rate of 0.02 mLÆmin
)1
and the break-
through was collected. The disk was then immersed in this
breakthrough and incubated for 24 h at room temperature.
Following the incubation, the disk was washed again with
5 volumes of buffer B and the remaining reactive groups
were blocked by loading 2 mL of 1 m ethanolamine in buf-
fer B at room temperature at a flow rate of 0.02 mLÆmin
)1
.
The disk was again immersed in the resulting breakthrough
for 24 h at room temperature and finally washed at 1 mLÆ
min
)1
with 5 volumes of buffer B containing 1 m NaCl,
and then with 5 volumes of water, and stored in 20% (v ⁄ v)
ethanol until use. Routinely, about 50% ofthe applied
AtxC was bound to the disk.
To isolate AIVAS, the CIM–AtxC disk was first equili-
brated in 10 mL of buffer A at a flow rate of 0.1 mL Æmin
)1
.
Two millilitres ofthe eluate fromthe LL-affinity chroma-
tography step was loaded at a flow rate of 0.02 mLÆmin
)1
,
and the unbound proteins were washed away with 10 mL
of buffer A at a flow rate of 0.1 mLÆmin
)1
. Bound proteins
were eluted with 0.1 m glycine ⁄ HCl, pH 2.8, containing
150 mm NaCl and 2 mm CaCl
2
. Fractions of 0.5 mL were
collected directly into 0.2 mL of 0.5 m Tris ⁄ HCl, pH 8.0,
containing 150 mm NaCl, and then immediately dialysed
into buffer A. The fractions were analysed by SDS ⁄ PAGE
as described previously [27,28].
Gel filtration chromatography
Gel filtration chromatography was performed on an A
¨
KTA
FPLC apparatus (Amersham Pharmacia Biotech). The frac-
tion fromthe CIM–AtxC affinity chromatography step
containing AIVAS was dialysed against buffer A and
applied to a Superdex 75 HR 10 ⁄ 30 column (Amersham
Pharmacia Biotech) previously calibrated with the follow-
ing molecular mass standards: Dextran blue (2000 kDa);
BSA (65 kDa); egg albumin (45 kDa); chymotrypsinogen
(25 kDa); cytochrome c (12.3 kDa); aprotinin (6.5 kDa);
and l-tyrosine (0.1 kDa). Proteins were eluted at 0.5 mLÆ
min
)1
with buffer A and 1-mL fractions were collected,
concentrated in Centricon YM-10 concentrators (Millipore,
Billerica, MA, USA) and analysed by SDS ⁄ PAGE, as
described previously [27,28]. In SDS ⁄ PAGE analysis under
nonreducing conditions, dithiothreitol was omitted from
the sample buffer.
Western blotting
Samples were run on SDS ⁄ PAGE [12.5% (w ⁄ v) polyacryl-
amide gels]. The gel was soaked in the blotting buffer:
25 mm Tris ⁄ HCl, pH 8.3, 192 mm glycine, 0.1% (w ⁄ v)
SDS, 20% (v ⁄ v) methanol. A semidry blotter (Biometra,
Go
¨
ttingen, Germany) was used for 15 min (2 W per
100 cm
2
of gel) at room temperature to transfer the pro-
teins fromthe gel to a nitrocellulose membrane (Costar,
Cambridge, MA, USA) for subsequent immunodetection or
to a PVDF membrane (Bio-Rad, Hercules, CA, USA) for
N-terminal sequence analysis.
Ammodytoxin inhibitorfromViperaammodytesserum J. S
ˇ
ribar et al.
6062 FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS
Deglycosylation
Deglycosylation was performed essentially as described pre-
viously [23]. To 0.1 lg of AIVAS in 18 lLof50mm
Na
2
HPO
4
, pH 7.5, 3 lL (3 U) of protein N-glycosidase F
(Roche, Mannheim, Germany) was added and incubated at
37 °C for 24 h. SDS ⁄ PAGE analysis, as explained above,
followed. In the control experiment, no protein N-glycosi-
dase F was added to the reaction mixture.
Immunodetection
The nitrocellulose membrane was incubated with rabbit
polyclonal anti-CICS IgG diluted 1 : 1000. The position of
specific proteins on the membrane was revealed using the
BM chemiluminescence western blotting kit (Roche Molec-
ular Biochemicals, Mannheim, Germany) following the
manufacturer’s instructions.
N-terminal sequence analysis
Proteins were detected on the PVDF membrane using Coo-
massie Brilliant Blue R250. Protein bands were excised and
analysed by automated Edman N-terminal sequencing anal-
ysis on an Applied Biosystems Procise 492 A protein-
sequencing system (Applied Biosystems, Foster City, CA,
USA).
Inhibition ofphospholipase activity
Isolated AIVAS was incubated in 50 l Lof50mm KCl,
1mm CaCl
2
,50mm Tris ⁄ HCl, pH 7.4, at room tempera-
ture for 30 min with 72 nm AtxC, at different molar ratios.
In the same way, AIVAS was incubated also with the repre-
sentatives of other structural types of sPLA
2
molecules –
0.4 and 2 molar parts of AIVAS were mixed with 1 part of
an sPLA
2
. In a 96-well plate, a 1 lL aliquot ofthe incuba-
tion mixture was added to 200 lL of 0.09% (w ⁄ v) BSA
(fatty-acid free) in 50 mm KCl, 1 mm CaCl
2
,50mm
Tris ⁄ HCl, pH 7.4, followed by 100 lL of a substrate, lipid
vesicles of 1-hexadecanoyl-2-(1-pyrenedecanoyl)-sn-glycero-
3-phosphoglycerol (4.2 l m) (Invitrogen, Carlsbad, CA,
USA) in the same buffer. Phospholipase activity was mea-
sured using a modified method of Radvanyi et al. [29]. Flu-
orescence was monitored in 10 kinetic cycles on a SAFIRE
microplate monochromator reader (Tecan, Salzburg, Aus-
tria) using the following parameters: excitation wavelength
342 nm, emission wavelength 395 nm, number of flashes 10
and integration time 40 ls. To determine the enzymatic
activity ofthe sample, the slopes ofthe curves were calcu-
lated, the background fluorescence subtracted and the
resulting value compared with that ofthe sample with
known enzymatic activity. To determine the background
fluorescence only AIVAS, without an sPLA
2
, was present.
To establish the full enzymatic activity of particular types
of sPLA
2
(100% value) only the sPLA
2
, without AIVAS,
was added to the reaction mixture.
Acknowledgements
This work was supported by grant P1-0207-0106 from
the Slovenian Ministry of Higher Education, Science
and Technology and by the PROTEUS program from
the same Slovenian Ministry and the French Ministry
of Foreign Affairs. We thank Maja Lang Balija from
the Institute of Immunology, Croatia, for kindly pro-
viding us with Vipera a. ammodytes serum; Adrijana
Leonardi from Jozˇ ef Stefan Institute, for performing
the protein N-terminal sequence analyses; and BIA
Separations, Slovenia, for their kind gift of CIM
Epoxy Discs. We sincerely thank Dr Roger H. Pain
for critical reading ofthe manuscript.
References
1 Dunn RD & Broady KW (2001) Snake inhibitors of
phospholipase A
2
enzymes. Biochim Biophys Acta 1533,
29–37.
2 Faure G (2000) Natural inhibitors of toxic phospho-
lipases A
2
. Biochimie 82, 833–840.
3 Fortes-Dias CL (2002) Endogenous inhibitors of snake
venom phospholipases A
2
in the blood plasma of
snakes. Toxicon 40, 481–484.
4 Ohkura N, Okuhara H, Inoue S, Ikeda K & Hayashi K
(1997) Purification and characterization of three distinct
types ofphospholipase A
2
inhibitors fromthe blood
plasma ofthe Chinese mamushi, Agkistrodon blomhoffii
siniticus. Biochem J 325, 527–531.
5 Kogaki H, Inoue S, Ikeda K, Samejima Y, Omori-Satoh
T & Hamaguchi K (1989) Isolation and fundamental
properties of a phospholipase A
2
inhibitor from the
blood plasma of Trimeresurus flavoviridis. J Biochem
(Tokyo) 106, 966–971.
6 Inoue S, Kogaki H, Ikeda K, Samejima Y & Omori-
Satoh T (1991) Amino acid sequences ofthe two sub-
units of a phospholipase A
2
inhibitor fromthe blood
plasma of Trimeresurus flavoviridis. Sequence homolo-
gies with pulmonary surfactant apoprotein and animal
lectins. J Biol Chem 266, 1001–1007.
7 Ohkura N, Inoue S, Ikeda K & Hayashi K (1993) Isola-
tion and amino acid sequence of a phospholipase A
2
inhibitor fromthe blood plasma of Agkistrodon blomh-
offii siniticus. J Biochem (Tokyo) 113, 413–419.
8 Okumura K, Ohno A, Nishida M, Hayashi K, Ikeda K
& Inoue S (2005) Mapping the region ofthe alpha-type
phospholipase A
2
inhibitor responsible for its inhibitory
activity. J Biol Chem 280, 37651–37659.
J. S
ˇ
ribar et al. Ammodytoxin inhibitorfromViperaammodytes serum
FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS 6063
9 Okumura K, Ohkura N, Inoue S, Ikeda K & Hayashi
K (1998) A novel phospholipase A
2
inhibitor with leu-
cine-rich repeats fromthe blood plasma of Agkistrodon
blomhoffii siniticus. Sequence homologies with human
leucine-rich alpha2-glycoprotein. J Biol Chem 273 ,
19469–19475.
10 Okumura K, Inoue S, Ikeda K & Hayashi K (2002)
Identification of beta-type phospholipase A
2
inhibitor
in a nonvenomous snake, Elaphe quadrivirgata. Arch
Biochem Biophys 408, 124–130.
11 Lizano S, Domont G & Perales J (2003) Natural phos-
pholipase A
2
myotoxin inhibitor proteins from snakes,
mammals and plants. Toxicon 42, 963–977.
12 Kini RM (1997) Venom Phospholipase A
2
Enzymes:
Structure, Function and Mechanism. John Wiley & Sons,
Chichester.
13 Schaloske RH & Dennis EA (2006) The phospholipase
A
2
superfamily and its group numbering system.
Biochim Biophys Acta 1761, 1246–1259.
14 Kudo I & Murakami M (2002) Phospholipase A
2
enzymes. Prostaglandins Other Lipid Med 68–69, 3–58.
15 Murakami M & Kudo I (2004) Secretory phospholipase
A
2
. Biol Pharm Bull 27, 1158–1164.
16 Hanasaki K & Arita H (2002) Phospholipase A
2
recep-
tor: a regulator of biological functions of secretory
phospholipase A
2
. Prostaglandins Other Lipid Med 68–
69, 71–82.
17 Krizˇ aj I & Gubens
ˇ
ek F (2000) Neuronal receptors for
phospholipases A
2
and beta-neurotoxicity. Biochimie 82,
807–814.
18 Lambeau G & Lazdunski M (1999) Receptors for a
growing family of secreted phospholipases A
2
. Trends
Pharmacol Sci 20, 162–170.
19 Faure G, Villela C, Perales J & Bon C (2000) Interac-
tion ofthe neurotoxic and nontoxic secretory phospho-
lipases A
2
with the crotoxin inhibitorfrom Crotalus
serum. Eur J Biochem 267, 4799–4808.
20 Lizano S, Lomonte B, Fox JW & Gutierrez JM (1997)
Biochemical characterization and pharmacological prop-
erties of a phospholipase A
2
myotoxin inhibitor from
the plasma ofthe snake Bothrops asper. Biochem J 326,
853–859.
21 Fortes-Dias CL, Lin Y, Ewell J, Diniz CR & Liu TY
(1994) A phospholipase A
2
inhibitor fromthe plasma of
the South American rattlesnake (Crotalus durissus terrif-
icus). Protein structure, genomic structure, and mecha-
nism of action. J Biol Chem 269, 15646–15651.
22 Perales J, Villela C, Domont GB, Choumet V, Saliou B,
Moussatche H, Bon C & Faure G (1995) Molecular
structure and mechanism of action ofthe crotoxin
inhibitor from Crotalus durissus terrificus serum. Eur J
Biochem 227, 19–26.
23 Dos Santos RM, Oliveira LC, Esteva
˜
o-Costa MI, de
Lima ME, Santoro MM & Fortes-Dias CL (2005) Inhi-
bition of crotoxin binding to synaptosomes by a recep-
tor-like protein from Crotalus durissus terrificus (the
South American rattlesnake). Biochim Biophys Acta
1717, 27–33.
24 Lizano S, Angulo Y, Lomonte B, Fox JW, Lambeau G,
Lazdunski M & Gutierrez JM (2000) Two phospho-
lipase A
2
inhibitors fromthe plasma of Cerrophidion
(Bothrops) godmani which selectively inhibit two differ-
ent group-II phospholipase A
2
myotoxins from its own
venom: isolation, molecular cloning and biological prop-
erties. Biochem J 346, 631–639.
25 S
ˇ
ribar J, C
ˇ
opic
ˇ
A, Paris
ˇ
A, Sherman NE, Gubens
ˇ
ek F,
Fox JW & Krizˇ aj I (2001) A high affinity acceptor for
phospholipase A
2
with neurotoxic activity is a calmodu-
lin. J Biol Chem 276, 12493–12496.
26 C
ˇ
opic
ˇ
A, Vuc
ˇ
emilo N, Gubens
ˇ
ek F & Krizˇ aj I (1999)
Identification and purification of a novel receptor for
secretory phospholipase A
2
in porcine cerebral cortex.
J Biol Chem 274, 26315–26320.
27 Laemmli UK (1970) Cleavage of structural proteins
during the assembly ofthe head of bacteriophage T4.
Nature 227, 680–685.
28 Merril CR, Goldman D, Sedman SA & Ebert MH
(1981) Ultrasensitive stain for proteins in polyacryl-
amide gels shows regional variation in cerebrospinal
fluid proteins. Science 211, 1437–1438.
29 Radvanyi F, Jordan L, Russo-Marie F & Bon C (1989)
A sensitive and continuous fluorometric assay for phos-
pholipase A
2
using pyrene-labeled phospholipids in the
presence ofserum albumin. Anal Biochem 177, 103–109.
Ammodytoxin inhibitorfromViperaammodytesserum J. S
ˇ
ribar et al.
6064 FEBS Journal 274 (2007) 6055–6064 ª 2007 The Authors Journal compilation ª 2007 FEBS
. understanding of the patho-
physiology of this group of enzymes.
In this work we present the characterization of the
first PLI from the serum of the most dangerous. The first phospholipase inhibitor from the serum
of Vipera ammodytes ammodytes
Jernej S
ˇ
ribar
1
, Lidija Kovac
ˇ
ic
ˇ
1
,